A series of 6a-tetrahydro-1H,4H-[1,3]dioxepino[5,6-b]azirines, 4, has
been synthesized and evaluated for its effects on blood glucose-decrea
sing activity. These derivatives were prepared from 4,7-dihydro-1,3-di
oxepins 1 via vic(acylamino)halogenodioxepanes 2 and, dioxepinoazirine
s 3. Quantitative structure-property relationship and quantitative str
ucture-activity relationship models, based on X-ray and molecular mech
anics analyses, to our knowledge the first in the field of antihypergl
ycemics, were developed. They allow the prediction of properties (RP-H
PLC attention times) and activities (hypoglycemic activity ratio) by t
he Connolly's molecular surface areas. The lead compound in these mode
ls, sulfonyldioxepinoazirine 4i, expressed superior antihyperglycemic
activity in comparison to metformin in alloxanized mice, irrespective
of route of application. It significantly reduced blood glucose levels
in glucose-primed mice, but it did not cause a dose dependent decreas
e of blood glucose level in healthy (nondiabetic, control) animals.